Cluster guide
You started an injection and something in your life stopped behaving the way it used to. Your resting heart rate moved. An easy run got hard. Food stopped talking to you. This cluster takes one question at a time and answers it from the trial data and the prescribing information, with the weak evidence labelled as weak.
Reduced drinking is now a randomised finding rather than a forum report. Separately, alcohol stacks badly with the GI and hypoglycaemia sides of the drug.
There is no documented drug interaction. There is a plausible additive effect on heart rate and on GI irritation, with much less food in the stomach to buffer either.
A soft wellness topic with a hard regulatory warning behind it: dehydration following GI symptoms is the documented route to acute kidney injury on this class.
Fatigue on a GLP-1 usually has a findable cause. Separate the fixable from the expected instead of accepting it.
The signal is real, the trial rates are low, and the leading mechanism is rapid weight loss rather than the drug itself. That distinction changes what can be done about it.
A weight-loss phenomenon with a drug's name attached. The useful content is why facial fat behaves differently and what rate of loss has to do with it.
GI effects are the dominant labelled adverse reactions, inseparable from how the drug works, and concentrated in escalation. The serious ones are a short, specific list.
Mostly a label-and-logistics page. The pharmacology is forgiving for weekly agents. Storage and border rules are where people get caught.
No direct evidence exists for either. The honest content is the compounding logic: heat and altitude both drive fluid loss and cut appetite, and the drug already does both.
Not a labelled adverse reaction. The plausible drivers are all downstream: fluid and electrolyte losses, reduced intake, changed training load.
The protein evidence predates GLP-1s and is solid. The new problem is not the target, it is reaching one when total food volume has halved.
No GLP-1-specific research exists. The honest page covers creatine's own evidence, the water-weight artefact and the creatinine-test artefact.
Tell the anaesthetic team you are on this drug. Perioperative guidance changed materially in October 2024, and the current version is risk-stratified rather than blanket.
One precise label instruction with a number of weeks attached, specific to tirzepatide and to oral contraceptives. Non-oral methods are unaffected.
The labels say stop before a planned pregnancy. The drug can also make you more fertile than you expected. Those two facts together are why people conceive unexpectedly on this class.
The labelled harm chain is short: GI symptoms, then dehydration, then kidney injury. Interrupting it early is the whole point, and whether to take your next dose is your prescriber's answer.
Two-thirds of the weight came back within a year in the trial extension. That number should shape the decision before you start, not after you stop.
The relative risk is real and quantified. The absolute risk is small. Rapid weight loss is a large part of the driver, and severe right upper abdominal pain needs assessment.
Blood pressure falls, heart rate rises. Both are expected. The practical issue is antihypertensive doses set for a heavier body.
Chronic protection and acute vulnerability at the same time. FLOW's benefit is specific to type 2 diabetes with CKD at 1.0 mg semaglutide. The acute risk runs through dehydration.
The label's own monitoring instruction is the operative fact. Reward-circuit involvement is real. Attribution is genuinely hard, and anything acute needs a person, not a page.
Endurance fuelling depends on the one thing this drug class slows. The conflict is real, the label documents the mechanism, and no trial has studied the sports-nutrition consequence.
Almost everyone on this drug trains closer to fasted by default. The question that matters is whether total daily protein is being met, not whether you ate beforehand.
Lean mass loss is real and measured. The trials that measured it mostly had nobody lifting, so treat those numbers as the untrained baseline rather than the drug's verdict.
Body mass falls, which helps. Glycogen availability falls and resting heart rate rises, which hurts. Aerobic fitness itself does not improve from the drug.
The pharmacology explains why food went quiet. Nothing pharmacological keeps it quiet after the prescription ends.
Sleep apnoea is the one sleep outcome with a trial and an approval behind it. Everything else here is much weaker evidence.
The heart-rate rise is real, labelled and small. The outcome trial found a 20% reduction in major cardiovascular events. Readers routinely conflate these.
Ozempic and Wegovy are the same molecule with different indications. The part that can hurt you is what happens when a GLP-1 lands on top of insulin or a sulfonylurea.
The question has two answers and most coverage gives only the first. An approved GLP-1 is not banned. An unapproved one is banned at all times under S0, and that is where athletes get caught
Evidence updates
Approvals move, trials read out, labels get rewritten. We re-check these pages against their primary sources and email what actually changed, with the citation next to it.
What you will not get: protocols, supplement offers, "wellness" or a drip sequence. If a month goes by and nothing worth sending has changed, we do not send anything.
Confirmed by email before anything is sent, so a typo cannot sign up a stranger. One-click unsubscribe in every message. The list is never shared or sold.